Penny Pick Finders
Penny Pick Finders

This NEW Nasdaq Bio-Tech is the ONLY stock for you Tuesday...

Email sent: May 23, 2020 11:06am

Is this your brand on Milled? You can claim it.


Hoth Therapeutics, Inc. Ticker Symbol HOTH


Dear Fellow Trader,


My New #1 biotech stock that could potentially more double in less than five months...


Immediately turn your attention to Hoth Therapeutics (HOTH)


This new biotech stock is shaping up to be the PERFECT PROFIT STORM of the decade!


And I am confident it could be our next potential ten-bagger opportunity in 2020.


I’m also going to show you exactly what you can do today to get your hands on my #1 biotech stock with ten-bagger potential!


Just How High Will This #1 Biotech

Stock Go... and Why?


Bombshell News Just Dropped!


Hoth Therapeutics is Working on a Potential Coronavirus 

Vaccine (COVID-19)


Hoth Therapeutics announced bombshell news that it has entered into a joint venture agreement with its joint venture partner, Voltron Therapeutics, for the “joint development for a Self-Assembling Vaccine (SAV) for the Potential Prevention of the Coronavirus (COVID-19).” Most notably, the SAV technology has been exclusively licensed by Hoth’s Joint Venture Partner from Massachusetts General Hospital with “Preclinical development to be undertaken in conjunction with Voltron Therapeutics and the Vaccine & Immunotherapy Center (VIC) at Massachusetts General Hospital.”


The joint entity will be called HaloVax. Based on VaxCelerate, this SAV platform was exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH). The VaxCelerate vaccine platform enables the rapid generation and pre-clinical testing of a new vaccine against specific pathogen targets.


The technology has obtained funding from the Department of Defense (DoD) and demonstrated proof of concept in Lassa Fever, which is an emerging infectious disease.

Both companies will jointly explore and develop this SAV technology as a means to help patients at risk of being infected with COVID-19. The vaccine focuses on both DNA and internal/external mutated proteins providing the immune system with more potential targets to attack.


Given the widespread outbreak of COVID-19, many pharma/biotech companies are joining the race to develop treatments for the same. In particular, efforts to develop a vaccine to combat this deadly virus have accelerated in the last couple of weeks and Hoth is the latest company to join this bandwagon.


Earlier, Moderna dosed the first participant in the phase I study of mRNA vaccine (mRNA-1273) against SARS-CoV-2. A few others like Novavax and Inovio Pharmaceuticals. INO are developing vaccines to address this disease. Big pharmas like Johnson & Johnson and GlaxoSmithKline are making efforts as well to develop a vaccine.


This Could Potentially Be Our NEXT Ten-Bagger

Biotech Stock You’ve Been Waiting For


It's important to note, my previous early-stage biopharmaceutical winner that provided you and other members 3,396% in Gains is not the only biotech stock I believe could rocket higher!


Drugs are expensive here in America. We can all agree on that, even if we disagree politically about what to do about it.


But there’s a flipside to the high prices we pay for medications. Our country’s biotech market funds most of the world’s drug research and development. And it has delivered incredible gains to investors over the years. If you had invested $10,000 in the S&P 500 10 years ago, you’d have more than $37,000 today. But if you had put it in the iShares Nasdaq Biotechnology ETF, you’d have approx. $50,000...


And that’s arguably the simplest and most passive biotech investing strategy possible. If you buy individual, early-stage biotech stocks at the right moments, you can see much bigger gains in much shorter time frames.


A $10,000 investment in my previous early-stage biopharmaceutical pick Co-Diagnostics would have ballooned into approx. $350,696 if you had bought when I first initiated coverage on it and gave it to you in early July at $.85 cents, and sold at its high last week of $29.72 on May 14th.


A $10,000 investment in my previous early-stage biopharmaceutical pick Axsome Therapeutics would have ballooned into approx. $219,880 if you had bought when I first alerted you in early January 2019 at $5.00 and sold at its high three weeks ago of $109.00 on April 27th.


A $10,000 investment in my previous early-stage biopharmaceutical pick Applied DNA Sciences would have ballooned into approx. $34,000 if you had bought when I first alerted you in April at $4.80 and sold at its high last week of $16.39 on May 14th.


What Makes Huge Gains Like This Happen So Quickly?


Put simply, these gains in small biotech stocks happen on important catalyst dates in the drug development process. These catalyst dates include clinical trial results, approval decisions, analyst coverage.


Analysts Issue $10.00 Price Target, 263% Gain From its Current Price! Tuesdays New Biotech Breakout Stock: Hoth Therapeutics (NASDAQ: HOTH)


While the prime focus is currently on coronavirus treatments and vaccines for the biotech sector, a few other updates were also out this past week. A slew of biotechs are evaluating their pipeline drugs and vaccines for the treatment of COVID-19 and updates from these companies could potentially send their share prices soaring!


Lighting The Fuse Of The Next New Nasdaq Biotech Breakout Stock HOTH


Next Catalyst, is its Novel Peptide COVID-19 Therapeutic Prevents Spike Protein Binding and Slows the Transmission of COVID-19.


More Bombshell News Just Dropped!


Hoth Therapeutics Licenses Novel Peptide COVID-19 Therapeutic


Peptide Prevents Spike Protein Binding and Slows the Transmission of COVID-19


Technology and intellectual property is licensed exclusively from Virginia Commonwealth University and invented by Michael H. Peters, Ph.D.


Hoth Therapeutics just announced licensing technology and intellectual property exclusively from Virginia Commonwealth University ("VCU") for a novel peptide therapeutic to prevent spike protein binding, which may be a leading cause of COVID-19, and slow its transmission.


The research is being led by inventor Michael H. Peters, Ph.D., Professor, Department of Chemical and Life Science Engineering at VCU, College of Engineering, and is being aided, in part, by powerful supercomputers as part of the COVID-19 High Performance Computing Consortium through a virtual system that scientists can use to interactively share computing resources known as the Extreme Science and Engineering Discovery Environment.


The consortium is a private-public partnership that includes the White House Office of Science and Technology Policy and major technology corporations.


SARS-CoV-2 or COVID-19 attaches to and enters cells through the binding of its perfusion Spike Protein to the cell surface receptor Angiotensin Converting Enzyme 2 (ACE2). ACE2 is a protein found on the surface of lung alveolar cells, cells of the small intestine, and arteriole cells making it highly dispersed throughout the body. Because of the wide-spread dispersion of ACE2 within the body, there are numerous opportunities for SARS-CoV-2 to infiltrate the body.


The spike in protein plays an important role in attaching to human cells and infecting the body. Researchers at VCU have developed at novel peptide that binds with extremely high affinity to SD1 segment of the SARS-CoV-2 spike protein mimicking its attachment to ACE2. This high binding affinity helps block the spike protein from attaching to the ACE2 surface receptor, thus limiting the transmission of the virus. Further development of the novel peptide can also allow a novel target for the SARS-CoV-2.


Dr. Peters commented, "The spike protein of the novel-corona-virus SARS-Cov-2 associated with the current COVID-19 pandemic uses a specific receptor on human epithelial cells, called ACE2, for its fusion and infection process. This therapeutic development effort exploits the unusually strong and unique binding of the SARS-Cov-2 spike protein to ACE2 to develop safe and effective peptide 'decoys' that have the potential to preferentially bind to the spike protein and prevent fusion and infection."


"Computer modeling of SARS-CoV-2's spike protein is an important step in finding ways to prevent the virus from binding to ACE2 receptors and allowing the virus to replicate," said Ivelina Metcheva, Ph.D., Senior Executive Director of VCU's Innovation Gateway. "We are very excited to assist Dr. Peter's collaboration with Hoth Therapeutics to develop potentially life-saving therapy for COVID-19."


"My team and Board have continued to see remarkable technologies that could have potential breakthroughs in the fight against COVID-19," said Robb Knie, CEO of Hoth Therapeutics. "Dr. Peters and his team have been working diligently on analyzing data surrounding the theory of SARS-CoV-2's spike protein, its potential effect on COVID-19 and developing a therapeutic that would be effective in limiting transmission of the virus."


The Bottom Line...


Analysts Issue $10.00 Price Target, 263% Gain From its Current Price! Tuesdays New Biotech Breakout Stock: Hoth Therapeutics (NASDAQ: HOTH)


You must take this particular stock very seriously, pay attention to the magnitude of their recent Bombshell News they've announced!


I am urging all of my members to add HOTH to the top of their watch list right now, and be ready Tuesday morning at the opening bell!

Happy Trading!

Your PPF Team

This message was sent to - from

Penny Pick Finders
99 Wall Street
New York, New York 10005

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

iContact - Try it for FREE

Other emails from Penny Pick Finders

Penny Pick Finders
Jul 8, 2020
See AIHS! WOW... Rockets Up 171% From My Initial Alert (Congrats)
Penny Pick Finders
Jul 2, 2020
See NXTD! WOW... Rockets up 280% from initial alert (Congrats)
Penny Pick Finders
Jun 29, 2020
MYCOF in total BREAKOUT Mode 100% BUY-Triggered + Congrats on Your 189% Gainer
Penny Pick Finders
Jun 29, 2020
Morning Reminder: MYCOF this one could FLY... 100% BUY-Triggered
Penny Pick Finders
Jun 28, 2020
Monday MYCOF Ready for Blast-Off Major Acquisition News
Penny Pick Finders
Jun 28, 2020
Monday MYCOF Ready for Breakout Major Acquisition News